# Kevin Gorman

> Kevin C. Gorman is a founder and former president and CEO of Neurocrine Biosciences. A UCLA-trained scientist with an MBA in finance and experience in venture formation, he helped establish Neurocrine in 1992, joined its staff in 1993, and served as CEO from January 2008 to October 2024. He remains a Neurocrine director and also serves on Xencor’s board.

- **Role:** Founder and Director at Neurocrine Biosciences; Director at Xencor
- **Organizations:** Neurocrine Biosciences, Xencor, Avalon Medical Partners
- **Education:** Ph.D. in Immunology, University of California, Los Angeles, M.B.A. in Finance, UCLA Anderson Graduate School of Management, Postdoctoral training, The Rockefeller University
- **Known for:** Helped found Neurocrine and served as its CEO from January 2008 through October 2024., Recognized in the Life Sciences category of EY’s 2018 Entrepreneur Of The Year San Diego awards., Listed as the 2018 national Life Sciences winner in EY’s Strategic Growth Forum highlights.

## Career timeline

- **1990–1993** — Principal at Avalon Medical Partners, involved in the early formation of Neurocrine and other companies.
- **1992** — Helped found Neurocrine Biosciences.
- **1993** — Joined Neurocrine’s staff as head of business development.
- **2006** — Appointed chief operating officer in September, after serving as chief business officer.
- **2008** — Appointed president, CEO, and director on January 14.
- **2010** — Led Neurocrine when it signed collaborations with Abbott and Boehringer Ingelheim on consecutive days in June.
- **2017** — Joined Xencor’s board in April.
- **2018** — Recognized in EY’s San Diego and national Entrepreneur Of The Year Life Sciences categories.
- **2024** — Retired as Neurocrine CEO on October 11; Kyle Gano succeeded him. Continued on the board.

## Achievements

- Helped found Neurocrine and served as its CEO from January 2008 through October 2024.
- Recognized in the Life Sciences category of EY’s 2018 Entrepreneur Of The Year San Diego awards.
- Listed as the 2018 national Life Sciences winner in EY’s Strategic Growth Forum highlights.
- Appointed to Xencor’s board in April 2017.

## Latest updates

- **2026-04** — Neurocrine’s 2026 proxy statement lists Gorman as a Class III director nominated for reelection.
- **2024-10** — Retired as president and CEO on October 11 and continued as a director.
- **2024-05** — Neurocrine announced Kyle Gano as CEO-elect and set an October 11 succession date.

## Links

- Website: https://www.neurocrine.com/leadership/
- LinkedIn: https://www.linkedin.com/in/kevin-gorman-4266076

---

Profile page: https://yespress.io/kevin-gorman
Published by YesPress — https://yespress.io
Last updated: 2026-10-24